Printable version

Hépato-Gastro. Volume 17, Number 1, 95-100, janvier-février 2010, Compte rendu de congrès

Résumé   Texte intégral

Author(s) : Benoît Coffin

Summary : During the 90s, the highlight of a visceral hypersensitivity in patients with irritable bowel syndrome (IBS) has been one of the major pathophysiological advances. These last 10 years have been marked by the discovery of a micro-inflammatory state that promotes the emergence of increased intestinal permeability. These two abnormalities are probably the essential elements that favors the development of this hypersensitivity. Rome III criteria are the latest diagnostic criteria for IBS. Infrequently used in clinical practice, these diagnostic criteria have clarified the prevalence and incidence of IBS and the related medical costs. Therapeutically, MeteoSpasmyl ® (association of alverine citrate and simeticone) has confirmed its efficacy by decreasing abdominal pain during a Phase IV study conducted by the judging criteria set by health agencies in the early 2000s.

Keywords : irritable bowel syndrome, inflammation, epidemiology, intestinal permeability, alverine citrate, simeticone